VG5Q Inhibitors
Chemical inhibitors of VG5Q function primarily by disrupting the angiogenesis signaling pathways in which VG5Q is known to play a role. SU5416, as a selective inhibitor of VEGF receptors, can lead to the functional inhibition of VG5Q by blocking the very signals that facilitate angiogenesis, a process crucial to VG5Q's activity. Similarly, Sorafenib and Sunitinib, by targeting multiple tyrosine protein kinases including VEGFR, disrupt the VG5Q-associated angiogenic pathways. These inhibitors bind to the active sites of these receptors, effectively shutting down the signaling cascade that would normally result from VEGF binding and activation. Pazopanib, which also inhibits VEGFR tyrosine kinase activity, follows this same inhibitory pattern, acting to prevent VG5Q from executing its role in promoting new blood vessel formation.
Moreover, Axitinib and Vandetanib selectively inhibit the VEGFR among other receptors. The blockade established by these chemicals impairs the signaling required for VG5Q to function in angiogenesis. Bevacizumab, while not a small molecule inhibitor, binds to VEGF itself, preventing its interaction with VEGFR and thereby indirectly suppressing the activity of VG5Q within the angiogenic pathway. Afatinib, which irreversibly binds to several receptor tyrosine kinases, including those involved in VEGF signaling, ensures a sustained inhibition of VG5Q's function. Regorafenib's broad-spectrum kinase inhibition includes those kinases involved in VG5Q's angiogenic signaling, and Cabozantinib's inhibition of VEGFRs and MET also leads to a functional inhibition of VG5Q. Lastly, Lenvatinib and Nintedanib, which inhibit multiple tyrosine kinase receptors, including VEGFRs, further corroborate the functional inhibition of VG5Q by intersecting and inhibiting the signaling pathways essential for VG5Q's role in angiogenesis.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib targets multiple tyrosine protein kinases, such as VEGFR, which are involved in angiogenesis. By inhibiting these receptors, Sorafenib can impede the angiogenic pathways that VG5Q is associated with, leading to the inhibition of VG5Q's pro-angiogenic functions. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is an inhibitor of receptor tyrosine kinases, including VEGFRs, and by inhibiting these receptors, it can disrupt the angiogenesis pathway. Since VG5Q is implicated in vascular development, the inhibition of VEGFRs by Sunitinib can also inhibit the function of VG5Q. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Pazopanib inhibits VEGFR tyrosine kinase activity, which is essential for angiogenesis. By inhibiting this receptor, Pazopanib can indirectly inhibit VG5Q by thwarting the angiogenic signaling pathways in which VG5Q is involved. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib selectively inhibits VEGFR, among other receptors. The inhibition of VEGFR can in turn inhibit VG5Q functionally by cutting off the signaling pathways necessary for VG5Q's role in the angiogenic process. | ||||||
Afatinib | 439081-18-2 | sc-364398 sc-364398A | 5 mg 10 mg | $114.00 $198.00 | 13 | |
Afatinib irreversibly binds to certain receptor tyrosine kinases, including VEGFR. This binding leads to the functional inhibition of VG5Q by blocking the angiogenic signaling pathways that VG5Q supports. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Regorafenib is a multi-kinase inhibitor that targets angiogenic, stromal, and oncogenic receptor tyrosine kinases. By blocking these pathways, Regorafenib can inhibit VG5Q function by disrupting the angiogenesis process in which VG5Q is implicated. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
Cabozantinib is a tyrosine kinase inhibitor that targets VEGFRs and MET. The inhibition of these receptors leads to the functional inhibition of the VG5Q protein by impeding the pathways VG5Q utilizes for promoting angiogenesis. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $182.00 $661.00 $1690.00 | 3 | |
Lenvatinib inhibits multiple tyrosine kinase receptors including VEGFRs. By inhibiting these receptors, it functionally inhibits VG5Q by disrupting its role in angiogenic signaling pathways, thus inhibiting the angiogenesis that VG5Q may promote. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $184.00 $321.00 | 2 | |
Nintedanib is a tyrosine kinase inhibitor that blocks VEGFRs. Inhibition of these receptors can lead to the functional inhibition of VG5Q by preventing the angiogenesis process, which is central to VG5Q's function. | ||||||